Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of extended-dose temozolomide in patients with melanoma.
Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB. Rietschel P, et al. Among authors: orlow i. J Clin Oncol. 2008 May 10;26(14):2299-304. doi: 10.1200/JCO.2007.14.5292. J Clin Oncol. 2008. PMID: 18467721 Clinical Trial.
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M; Genes Environment and Melanoma Study Group. Begg CB, et al. Among authors: orlow i. J Natl Cancer Inst. 2005 Oct 19;97(20):1507-15. doi: 10.1093/jnci/dji312. J Natl Cancer Inst. 2005. PMID: 16234564 Free article.
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Busam K, From L, Mujumdar U, Wilcox H, Begg CB; GEM Study Group. Berwick M, et al. Among authors: orlow i. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1520-5. doi: 10.1158/1055-9965.EPI-06-0270. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16896043
CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA, Mujumdar U, Canchola R, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Wilcox H, Busam K, From L, Berwick M; GEM Study Group. Orlow I, et al. J Invest Dermatol. 2007 May;127(5):1234-43. doi: 10.1038/sj.jid.5700689. Epub 2007 Jan 11. J Invest Dermatol. 2007. PMID: 17218939 Free article.
Evaluation of the clonal origin of multiple primary melanomas using molecular profiling.
Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Orlow I, et al. J Invest Dermatol. 2009 Aug;129(8):1972-82. doi: 10.1038/jid.2009.4. Epub 2009 Mar 12. J Invest Dermatol. 2009. PMID: 19282844 Free PMC article.
Vitamin D receptor polymorphisms in patients with cutaneous melanoma.
Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Thomas NE, Gruber SB, Anton-Culver H, Rosso S, Gallagher RP, Dwyer T, Kanetsky PA, Busam K, From L, Begg CB, Berwick M; GEM Study Group. Orlow I, et al. Int J Cancer. 2012 Jan 15;130(2):405-18. doi: 10.1002/ijc.26023. Epub 2011 Apr 25. Int J Cancer. 2012. PMID: 21365644 Free PMC article.
214 results